Applicant, as named in the Orange Book
Exelixis Inc
Next listed expiry: Cabometyx on 9 Jul 2033. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Cabometyx · 3 strengths cabozantinib s-malate | cabozantinib s-malate | 208692 | 9 Jul 2033 | patent |
Recent events
- 25 Oct 2026Cabometyx · First generic approved 14 Aug 2026
- 25 Oct 2026Cabometyx · Generic approved 14 Aug 2026
- 25 Oct 2026Cabometyx · Generic approved 16 Oct 2026